Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$27.15 – $37.78
5% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $288.8M | $834.9M | $478.1M | $484.8M | $241.2M | $239.7M | $275.6M | $1.11B |
| Cost of revenue | $322.9M | $420.1M | $523.7M | $1.6M | $31.4M | $38.9M | $34.9M | $29.7M |
| Gross profit | −$34.0M | $414.8M | −$45.6M | $483.2M | $241.2M | $239.7M | $240.8M | $1.08B |
| Gross margin | -11.8% | 49.7% | -9.5% | 99.7% | 100.0% | 100.0% | 87.4% | 97.3% |
| R&D | $322.9M | $420.1M | $523.7M | $491.7M | $269.8M | $241.3M | $335.5M | $459.4M |
| Operating income | −$44.8M | $368.7M | −$178.6M | −$165.6M | −$131.1M | −$88.3M | −$188.3M | $501.4M |
| EBITDA | −$28.9M | $374.2M | −$170.7M | −$100.9M | $3.9M | $51.0M | $43.3M | $359.0M |
| Net income | −$29.3M | $149.8M | −$305.4M | −$125.4M | −$218.0M | $211.7M | $74.1M | $320.9M |
| Net margin | -10.1% | 17.9% | -63.9% | -25.9% | -90.4% | 88.3% | 26.9% | 28.9% |
| EPS (diluted) | -0.56 | 2.60 | -4.78 | -1.91 | -3.32 | -0.06 | 1.12 | 4.85 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26M | $-2.71 | $-6.36–$-0.70 | 3 |
| 2027 | $40M | $-2.44 | $-5.32–$0.47 | 3 |
| 2028 | $29M | $-3.38 | $-4.27–$-2.34 | 1 |
| 2029 | $38M | $-2.40 | $-3.03–$-1.66 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds GLPG.
No tracked institution reports a position in GLPG as of their last filing.
No one on the platform has traded GLPG yet.
| $3.0B |
| — |
| IBRXImmunityBio, Inc. | $8.71 | +0.10% | $9.1B | — |
| MESOMesoblast Limited | $13.55 | +2.77% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.3× sales vs its 7.5× historical median P/S.
Fair value ≈ $33.01 · price $27.73 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.